Frontiers in Neuroscience (Nov 2023)

Circulating plasma miR-23b-3p as a biomarker target for idiopathic Parkinson's disease: comparison with small extracellular vesicle miRNA

  • Sanskriti Rai,
  • Prahalad Singh Bharti,
  • Rishabh Singh,
  • Simran Rastogi,
  • Komal Rani,
  • Vaibhav Sharma,
  • Priya Kumari Gorai,
  • Neerja Rani,
  • Bhupendra Kumar Verma,
  • Thota Jagadeshwar Reddy,
  • Gyan Prakash Modi,
  • Krishna Kishore Inampudi,
  • Hem Chandra Pandey,
  • Sanjay Yadav,
  • Roopa Rajan,
  • Fredrik Nikolajeff,
  • Saroj Kumar,
  • Saroj Kumar

DOI
https://doi.org/10.3389/fnins.2023.1174951
Journal volume & issue
Vol. 17

Abstract

Read online

BackgroundParkinson's disease (PD) is an increasingly common neurodegenerative condition, which causes movement dysfunction and a broad range of non-motor symptoms. There is no molecular or biochemical diagnosis test for PD. The miRNAs are a class of small non-coding RNAs and are extensively studied owing to their altered expression in pathological states and facile harvesting and analysis techniques.MethodsA total of 48 samples (16 each of PD, aged-matched, and young controls) were recruited. The small extracellular vesicles (sEVs) were isolated and validated using Western blot, transmission electron microscope, and nanoparticle tracking analysis. Small RNA isolation, library preparation, and small RNA sequencing followed by differential expression and targeted prediction of miRNA were performed. The real-time PCR was performed with the targeted miRNA on PD, age-matched, and young healthy control of plasma and plasma-derived sEVs to demonstrate their potential as a diagnostic biomarker.ResultsIn RNA sequencing, we identified 14.89% upregulated (fold change 1.11 to 11.04, p < 0.05) and 16.54% downregulated (fold change −1.04 to −7.28, p < 0.05) miRNAs in PD and controls. Four differentially expressed miRNAs (miR-23b-3p, miR-29a-3p, miR-19b-3p, and miR-150-3p) were selected. The expression of miR-23b-3p was “upregulated” (p = 0.002) in plasma, whereas “downregulated” (p = 0.0284) in plasma-derived sEVs in PD than age-matched controls. The ROC analysis of miR-23b-3p revealed better AUC values in plasma (AUC = 0.8086, p = 0.0029) and plasma-derived sEVs (AUC = 0.7278, p = 0.0483) of PD and age-matched controls.ConclusionWe observed an opposite expression profile of miR-23b-3p in PD and age-matched healthy control in plasma and plasma-derived sEV fractions, where the expression of miR-23b-3p is increased in PD plasma while decreased in plasma-derived sEV fractions. We further observed the different miR-23b-3p expression profiles in young and age-matched healthy control.

Keywords